Aquila’s Post

The future is promising and full of perspectives…

Technological innovations now in development hold the key not just to living longer, but living better. Here's what investors looking to benefit from these advances need to consider in the broader market. Here are the 10 "longshot" technologies to watch.

#ALS/#MND Symposium 2024 is a wrap! QurAlis' CEO and founder Kasper Roet (center right side of the monitor) and several team members attended the 35th International Symposium on ALS/MND held last weekend. QurAlis was honored to sponsor this important meeting, engage with the ALS community, and participate in great scientific exchange about the latest advances in ALS/MND. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

Update: Additional BCI+ Summit Takeaways: BCI participants deserve compensation for their contributions, as highlighted by Ian Burkhart Engage with the FDA early on for valuable insights at no cost, advised by Carlos Pena Infuse creativity into your BCI business plan, emphasized by Ashwini Sharan Rebecca Monteleone from IEEE Brain stresses treating BCI as a sociotechnological system. Zane Arp underscores the importance of "reasonable" assurance of safety and effectiveness. Rob Franklin points out that failure to plan for scaling (COGS) can hinder product launch success. Emily Caporello Bluvas highlights how NIH Small Business programs support fundraising and commercial launch success. David McMullen notes non-clinical testing as a common reason for IDE disapprovals. Save the date for the iBCI Collaborative Community Inaugural Annual Meeting on 9/18/2024 in Silver Spring, MD, shared by Jennifer French. Let's collaborate and break silos to advance iBCI technology collectively, as Jose L Contreras-Vidal, Ph.D. emphasizes the community's collective success. Thanks to all participants! IUCRC BRAIN CENTER Peter Konrad Radhey Sharma #neurotech #medtech #innovation #neuromodulation #braincomputerinterface #AI Thanks to our sponsors and participating companies: Medtronic Precision Neuroscience Blackrock Neurotech Synchron

GoodSAM is a life saving program that allows anyone with first aid training to literally help save lives. Operating in several countries around the world including the UK, New Zealand, and parts of Australia (Victoria and most recently NSW), the app allows ambulance services to notify volunteers, with first aid training, of nearby emergencies. As part of a clinical trial, GoodSAM provided a cohort of volunteers with an ultra portable CellAED AED from Rapid Response Revival®. Several have already been used in emergency situations. In order to maintain the integrity of the trial, the trial's researchers are very effectively scrubbing the internet of any mention of the trial or CellAED. While disappointing for Rapid Response Revival and CellAEDs, it's great to occasionally see a glimpse of program (and devices) and how they're really changing people's lives. https://lnkd.in/gVTHfGPe The results of the trial are not expected to be published until 2025, but given it's been extended from the initial cohort I feel safe assuming that the trial and the CellAEDs, have passed the initial safety and efficacy hurdles. You can read more about the clinical trial here: https://lnkd.in/gtptRz9t Anyone with first aid training who's interested in learning more about how they can get involved and potentially help save their neighbours' lives, can download the GoodSAM app, or check out their website: https://lnkd.in/gt_HwmVX

Don't miss out on our latest read about the recent project consortium meeting!🔔 This news article covers all the key discussions, decisions, and future plans that were outlined during the meeting 👀 Stay informed and be a part of our journey as we continue to make strides towards our goals. Your engagement and support are crucial to our success 👏 Catch up on the latest developments and let us know your thoughts! 📖💬 🔗 https://lnkd.in/dV5bwWzs #HorizonEU #breastcancer #cancerresearch #radiomics #Consortium

How does NCX 470, our de-risked compound in Phase 3 development for #glaucoma, work? And why can it offer potential benefits to patients? Data from our first pivotal trial, ‘Mont Blanc’, show that the dual mechanism of action of NCX 470 can achieve greater intraocular pressure (IOP)-lowering – the only clinically proven method to slow progression of glaucoma - compared to the standard or care, latanoprost. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of the lowering of IOP through the primary outflow route, working via the trabecular meshwork. Bimatoprost, an established prostaglandin analog (PGA) also known as Lumigan®, primarily lowers IOP by increasing the outflow of aqueous humor through the uveoscleral pathway from the inner chambers of the eye. NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop, designed to leverage the potent effects in lowering of both NO and bimatoprost. It works by releasing NO and bimatoprost into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension.   You can see this explained in a video on our website: https://lnkd.in/d8HDbTTR. Results from Mont Blanc showed the IOP-lowering effect from baseline was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for latanoprost. Statistical non-inferiority was met vs. latanoprost in the primary efficacy analysis consistent with the efficacy requirements for approval in the U.S. In addition, 4 out of 6 timepoints demonstrated statistical significance in favor of NCX 470. We are now looking forward to seeing confirmation of this clinical profile with the results from the ongoing “Denali” Phase 3 trial, expected in Q3 2025. #Glaucoma #MedicalInnovation #Ophthalmology #NCX470 #Biotech 

The Florida Research and Innovation Center (FRIC) is a key driver in Cleveland Clinic’s mission to attract and retain top talent in the Florida region. With leaders from Cleveland Clinic Florida, Cleveland Clinic Innovations, and BioFlorida, the FRIC is making a profound impact on cutting-edge research in cancer, virology, and immunology. Through collaborative partnerships, the FRIC is creating new opportunities to transform patient care, developing innovative treatments that have the potential to improve and save lives. Watch this insightful video to learn more about the transformative work happening at FRIC and the future of medical research in Florida. 🔗 https://hubs.li/Q02-_WSC0 #Innovation #Research #Healthcare #ClevelandClinic #CancerResearch #FloridaResearch #BioFlorida #MedicalAdvancements #FutureOfMedicine #PatientCare #HealthcareInnovation

🚀 Prepare to be energized by a brand-new offering for #2024NPC: Ignite Sessions, designed to spark insightful conversations and foster meaningful collaborations outside the traditional meeting room setting. These six 10-minute powerhouse presentations, followed by engaging Q&A, are set to change the way we collaborate and innovate within the Proton Therapy community. Here's what's on the agenda: 1. Shielding Using Existing Linac Rooms: Dive into practical solutions with Niek Schreuder from Leo Cancer Care.    2. Designing & Developing a Proton Therapy Center Addition or Renovation: Uncover architectural innovation with Franck Le Bousse, Stantec. 3. Evolving Programs and Engaging Patients: Explore patient engagement strategies with Shelley Saunders, Mary Callahan, and Fern Nibauer-Cohen from Penn Medicine, University of Pennsylvania Health System. 4. Stop Wasting Time, Start Seeing Results: Discover how to modernize Prior Authorization with a software solution from Christopher Gonzalez, Apollo Healthcare. 5. DynamicArc: Optimizing the Gantry Solution: Delve into technical advancements with Frédéric Genin, IBA. 6. Economics of Radiation Oncology in the US Healthcare Sector: Examine the financial landscape with a focus on Proton Innovation and New Technology by Ron DiGiaimo, RC Billing. Don’t miss this opportunity to ignite new ideas for the future of Proton Therapy. Only two weeks left to secure your spot at NPC: https://lnkd.in/gjsPVg_4 #ProtonTherapy #Innovation #Collaboration #Networking